Print（PDF/169KB） Jun. 26, 2025 Corporate

Sumitomo Pharma Announces Organizational Realignment

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) announced today that the Company has implemented the following organizational realignment, effective June 26, 2025.

Organizational Realignment (effective June 26, 2025)

Secretariat, Audit & Supervisory Board is renamed to Audit and Supervisory Committee Office.

• *At the 205th Ordinary General Shareholders’ Meeting held today (June 26, 2025), the transition to an "Audit & Supervisory Committee" was approved. Accordingly, Secretariat, Audit & Supervisory Board is renamed to Audit and Supervisory Committee Office.